This was a prospective cohort study of adults aged 18 years or older initiating anti‑tuberculosis (TB) treatment at four clinics in Kampala, Uganda. Enrollment occurred between June 2024 and June 2025. Participants were followed for six months to assess clinical status, health‑related quality of life (HRQoL), sputum bacillary clearance and WHO‑defined TB treatment outcomes.
Long‑term conditions (LTCs) were identified using a combination of participant self‑report, validated screening instruments, clinical examination and blood analysis. Definitions for LTCs were informed by a Delphi consensus cited in the study (Ho et al.). Multimorbidity was defined specifically as TB plus two or more LTCs.
Among 254 adults with TB enrolled in the cohort, the prevalence of multimorbidity was 39.4% (95% CI 33.3–45.7%). Only 22.4% of participants had TB with no co‑existing condition. The most prevalent co‑existing conditions were HIV (44.1%), undernutrition (39.8%) and depression (16.1%). The study reports that multimorbidity affected approximately two in five adults with TB in this cohort.
The investigators examined cascades of care for selected conditions: HIV, diabetes mellitus, hypertension and mental health disorders. Analyses revealed substantial and condition‑specific gaps across the cascades. Notably, there were important failures in screening and diagnosis for HIV, diabetes mellitus and mental health conditions. Gaps in treatment delivery were particularly apparent for hypertension. These findings highlight missed opportunities within routine TB care to identify and manage co‑existing LTCs.
At enrolment, participants with multimorbidity had worse physiological status as measured by the National Early Warning Score (NEWS). The adjusted mean difference in NEWS associated with multimorbidity was 0.88 (95% CI 0.36 to 1.42). Multimorbidity was also associated with lower health‑related quality of life; the adjusted mean difference in HRQoL score was −10.75 (95% CI −16.77 to −4.73). These associations indicate multimorbidity was linked to both objectively worse clinical status and worse patient‑reported health at the time of TB diagnosis.
The study assessed sputum bacillary clearance using the TB‑Molecular Bacterial Load Assay (TB‑MBLA). Multimorbidity was associated with a higher risk of a positive TB‑MBLA at month 2, indicating delayed or reduced bacteriological clearance among those with multiple co‑existing LTCs. In regression analyses, multimorbidity was linked to a higher risk of an unsuccessful TB treatment outcome; the adjusted risk difference was 9.88% (95% CI 2.59 to 17.17).
All deaths that occurred during follow‑up were among participants classified with multimorbidity. The authors emphasise that multimorbidity was associated with both worse health at diagnosis and poorer TB treatment outcomes in this cohort. They argue that National TB programmes are well positioned to identify and manage co‑existing long‑term conditions, but the observed care cascades show gaps at different stages for different conditions. The findings support the need for tailored, integrated approaches to screening, diagnosis and management of LTCs within TB services.
The dataset contains sensitive health information, including HIV status and mental health conditions, and cannot be shared publicly owing to the potential for participant re‑identification. Pseudonymised data are held by the Infectious Diseases Institute (IDI), Makerere University, under the study's data management agreement; researchers who meet criteria for access can request data via IDI’s standard operating procedures. Analysis code will be made available on GitHub as reported in the source. Ethical approvals were obtained from the University of St Andrews School of Medicine Ethics Committee, the Infectious Diseases Institute Research Ethics Committee and the Uganda National Council of Science and Technology, and participant consent procedures were followed according to the authors.